Novan, a developer of dermatology treatments, has landed an amended licensing agreement with a Japanese firm that is worth an $11 million upfront payment and milestone payments as well as royalties.
Read MoreBob Ingram, chairman of Novan, a Morrisville-based company that specializes in nitric-oxide based therapies for skin conditions, has purchased $142,000 in company stock,
Read MoreThe chief commercial officer of Novan Inc., a pharmaceutical development company, abruptly resigned last week, according to a filing with the Securities and Exchange Commission.
Read MoreBiotechnology company KNOW Bio, a spinoff from Novan, has raised another $4.6 million in an equity offering, according to a filing with the Securities and Exchange Commission.
Read More
